#AS­CO18: Ab­b­Vie con­vinces one top an­a­lyst that its $6B 'megablock­buster' Ro­va-T is worth­less

7 years ago
R&D

Prep­ping a drug launch, Zai Lab poach­es As­traZeneca’s top can­cer drug sales ex­ec in Chi­na

7 years ago
People
China

Hours af­ter fil­ing $150M IPO, Tri­ci­da shares pos­i­tive PhI­II tri­al re­sults on CKD drug

7 years ago
Financing

With $1.2B NASH deal be­hind them, Nim­bus rais­es $65M for I/O, oth­er R&D

7 years ago
Financing

Fol­low­ing FDA win, Por­to­la los­es CEO William Lis

7 years ago
People

Ar­a­vive merges with strug­gling Ver­sar­tis, gain­ing ac­cess to Nas­daq; Si­lence Ther­a­peu­tics CEO Ali Mor­taza­vi leaves the ...

7 years ago
News Briefing

Sarep­ta snags its part­ner's CSO, Louise Rodi­no-Kla­pac, to lead new gene ther­a­py unit

7 years ago
People

Vaxart re­ports PhII de­feat for a lega­cy an­tivi­ral from Avi­ra­gen — shares slide

7 years ago
R&D

#AS­CO18: Bris­tol-My­ers takes an­oth­er stab at a pos­i­tive im­pres­sion for Check­Mate-227

7 years ago
R&D

With com­pe­ti­tion on its heels, Blue­print takes three can­cer drugs to Chi­na

7 years ago
China
Pharma

Nek­tar wants every­one to stay calm as they car­ry on with NK­TR-214, but #AS­CO18 spurs a stam­pede

7 years ago
R&D

Stan­ford spin­out Forty Sev­en ar­rives at AS­CO with a snap­shot of promis­ing CD47 da­ta — and a $115M IPO in hand

7 years ago
Financing
R&D

Roche dumps its PhI­II PI3K ef­fort on taselis­ib af­ter re­searchers track poor sur­vival edge, harsh side ef­fects for ...

7 years ago
R&D

Mer­ck­'s Keytru­da builds a com­mand­ing lead in front­line lung can­cer with da­ta from two more land­mark tri­als

7 years ago
R&D

Spurring move to per­son­al­ized ther­a­pies, Loxo el­bows its way back in­to the AS­CO spot­light with 2nd tis­sue-ag­nos­tic ...

8 years ago
R&D
Pharma

Roche boasts of stalling lung can­cer with Tecen­triq/chemo com­bo -- but ri­val Mer­ck stays out front

8 years ago
R&D

Blue­bird, Cel­gene add a promis­ing chap­ter to their suc­cess sto­ry with BC­MA-tar­get­ing CAR-T — and turn it around ...

8 years ago
R&D

FDA stalls yet an­oth­er Her­ceptin copy­cat, is­su­ing re­sponse let­ter to Am­gen/Al­ler­gan

8 years ago
Pharma

FDA quash­es block­buster dreams at Eli Lil­ly and In­cyte, of­fer­ing a se­vere­ly lim­it­ed ap­proval for Olu­mi­ant

8 years ago
Pharma

Bio­gen snatch­es ex-Pfiz­er ex­ec as new EVP, cor­po­rate de­vel­op­ment; Io­n­is/Akcea get thumbs up from EMA com­mit­tee on ...

8 years ago
News Briefing

The FDA and the EMA go their sep­a­rate ways on DMD: CHMP slaps down Sarep­ta but of­fers ri­val PTC an ex­pand­ed mar­ket

8 years ago
Pharma

Roche dumps its late-stage SMA drug af­ter gam­bling up to $545M-plus on the pro­gram

8 years ago
R&D

Neoanti­gen pi­o­neer Neon Ther­a­peu­tics casts off in search of $115M IPO to fu­el the race to a per­son­al­ized can­cer ...

8 years ago
Financing

Di­min­ish­ing the FDA’s pow­er was my in­tent: Right-to-try au­thor scolds Scott Got­tlieb as agency im­ple­ments new law

8 years ago
Pharma
First page Previous page 1031103210331034103510361037 Next page Last page
A service from the Financial Times